FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
forum

LALPATHLAB Share Price Discussion

Dr. Lal Path Labs Ltd.
NSE: LALPATHLAB | BSE: 539524 | ISIN: INE600L01024 | Sector: Pharmaceuticals and health care

Type
Buy
Instrument
LALPATHLAB
Entry Price
₹2,167
Price@Trade
₹2,167
Target Price
₹5,000
Stop Price
₹1,500
Valid Till
Nov 11, 2021 3:20 AM
Margin
₹173,360 approx for 80 Qty
Status
Exited
Exit Price
₹2,255.7
Net P&L
+₹7,096 (+4.09%)
Like
Reply (1)
NSE:LALPATHLAB price when posted: 2,167
1 Replies
Kapil Sahu @kapilsahu
Nov 23, 2020 3:29 AM

Update
Exited
Exit Price
₹2,255.7
Net P&L
+₹7,096 (+4.09%)
Recent posts in LALPATHLAB

Type
Buy
Instrument
LALPATHLAB JAN21 2300 CE
Entry Price
₹32.25
Price@Trade
₹32.25
Target Price
₹75
Stop Price
₹0
Valid Till
Jan 21, 2021 3:20 AM
Margin
₹8,062.5 approx for 250 Qty
Status
Exited
Exit Price
₹39
Net P&L
+₹1,687.5 (+20.93%)
Like
Reply (1)
H
Reputation: 98,847 • Jan 19 8:52 AM

Type
Buy
Instrument
LALPATHLAB
Entry Price
₹2,271.65
Price@Trade
₹2,271.65
Target Price
₹2,400
Stop Price
₹2,210
Valid Till
Feb 19, 2021 3:20 AM
Margin
₹2,271.65 approx for 1 Qty
Status
Exited
Exit Price
₹2,297
Net P&L
+₹25.35 (+1.12%)
Like
Reply (1)
N
Reputation: 10,430 • Jan 18 4:58 AM
Dr. Lal PathLabs Q3 PAT Seen Up 27.4% YoY To Rs. 54.1 Cr: Prabhudas Lilladher
Net Sales are expected to increase by 16.1 percent Y-o-Y (down 11.8 percent Q-o-Q) to Rs. 327.9 crore, according to Prabhudas Lilladher.
Moneycontrol
Like
Reply
B
Reputation: 700 • Jan 15 3:17 AM

Type
Sell
Instrument
LALPATHLAB
Entry Price
₹2,311
Price@Trade
₹2,318.55
Target Price
₹2,266
Stop Price
₹2,355
Valid Till
Jan 15, 2021 3:20 AM
Margin
₹231,100 approx for 100 Qty
Status
Exited
Exit Price
₹2,295.3
Net P&L
+₹1,570 (+0.68%)
Like
Reply (2)
G
GGK  lock  @ggk
Reputation: -3,779 • Jan 14 3:06 AM

Type
Sell
Instrument
LALPATHLAB
Entry Price
₹2,395
Price@Trade
₹2,383.5
Target Price
₹2,368
Stop Price
₹2,403
Valid Till
Jan 14, 2021 3:20 AM
Margin
₹23,950 approx for 10 Qty
Status
Expired before entry
Like
Reply (1)

📍📍Thyrocare Technologies … significant business revival in Q3 . Positive for diagnostic stocks.. Expects positive for Lal Path, Metropolis

· Thyrocare says - significant business revival in Q3 after business activities resumed across all states. The non-Covid business in par...
Read more...
1
Reply